Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Xilio Therapeutics, Inc.

Ticker
XLO
Sector
Industry
Report date
November 10, 2026
Valye AI Score

80

Very high visibility
Recent developments
Recent developments summary

Recent developments include clinical progress with FDA clearance for XTX501 Phase 1/2 trial, leadership changes, and quarterly financial results showing losses but some revenue strength.

Recent developments:
  • Xilio Therapeutics announced FDA clearance of an IND application for its XTX501 candidate to begin a Phase 1/2 clinical trial as of August 2026 [N1].
  • The company appointed Yariv Houvras as Chief Medical Officer in September 2026, enhancing its clinical leadership team [N1].
  • Xilio reported a net loss of $5.95 million and basic and diluted EPS of -$0.30 for the quarter ended September 30, 2026, with strong liquidity including $122.2 million in cash and equivalents [S2].
  • The company reported Q1 2026 results showing a loss but revenue exceeding expectations, indicating some commercial progress [N1].
  • Xilio has presented updated Phase 2 data for Vilastobart combined with Atezolizumab at the 2025 ASCO Annual Meeting, demonstrating ongoing clinical development [N8].
Overview

Xilio Therapeutics, Inc. operates as a clinical-stage biotechnology company developing tumor-activated immuno-oncology therapies. Its pipeline includes candidates such as Vilastobart and XTX501, targeting metastatic colorectal cancer and other oncology indications. The company engages in clinical trials, regulatory filings, and data presentations to advance its therapeutic candidates. Xilio has raised capital through public offerings to support its development programs and maintains a focus on innovative cancer treatments leveraging immune system activation within tumors.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Xilio Therapeutics, Inc. is a clinical-stage biotech company focused on tumor-activated immuno-oncology therapies. The company has reported ongoing clinical progress including FDA clearance for a Phase 1/2 trial of XTX501 and preliminary Phase 2 data for Vilastobart. Recent leadership appointments and capital raises have been disclosed. The latest SEC 10-Q filing as of September 30, 2026, shows strong liquidity with $122.2 million in cash and equivalents and a current ratio of 4.72, alongside a net loss of $5.95 million for the quarter.

Scenarios for XLO

Bull case model:

Xilio's clinical progress, including FDA clearance for XTX501's Phase 1/2 trial and promising Phase 2 data for Vilastobart, supports the potential for advancing novel immuno-oncology therapies. The company's strong liquidity position and recent capital raises provide financial resources to sustain development activities. Leadership appointments such as the new Chief Medical Officer may enhance clinical and regulatory execution. Continued clinical data updates and regulatory milestones could enhance business model clarity and investor confidence.

Bear case model:

Xilio faces risks typical of clinical-stage biotechnology companies, including clinical trial failures, regulatory setbacks, and the need for ongoing capital to fund operations. Recent quarterly losses and some missed revenue expectations highlight financial challenges. The company's success depends on the ability to demonstrate safety and efficacy of its pipeline candidates and to navigate competitive oncology markets. Delays or negative clinical outcomes could impact business model visibility and operational continuity.

Moat:

Xilio Therapeutics' moat is primarily based on its proprietary tumor-activated immuno-oncology platform and clinical-stage pipeline, which includes novel therapeutic candidates such as Vilastobart and XTX501. The company's focus on combining tumor activation with immune checkpoint inhibitors aims to differentiate its therapies in the oncology market. Intellectual property, clinical trial data, and regulatory progress contribute to its competitive positioning. However, as a clinical-stage biotech, its moat is contingent on successful clinical development and regulatory approvals.

Risks overview
Risks summary
The primary risks for Xilio Therapeutics relate to clinical development uncertainties, regulatory approval challenges, financial sustainability, and competitive pressures in the oncology immunotherapy sector.
Risks details:

• Clinical Development Risk: The company’s pipeline is in early clinical stages, and failure to demonstrate safety and efficacy could materially impact its business prospects.
• Regulatory Risk: Obtaining regulatory approvals is uncertain and delays or denials could affect the company’s ability to commercialize its therapies.
• Financial Risk: Ongoing losses and the need for additional capital raise risks dilution and financial strain if funding is not secured on favorable terms.
• Competitive Risk: The oncology immunotherapy market is highly competitive with many companies developing similar therapies, which may limit market opportunities.

FINAL FORECAST FOR XLO

Final take one line
Xilio Therapeutics exhibits very high visibility through detailed clinical progress, financial disclosures, and leadership updates, reflecting a clinical-stage biotech focused on tumor-activated immuno-oncology therapies.
Final take 12 to 24 month view

Business trends: Continued clinical development of tumor-activated immuno-oncology candidates with regulatory milestones and data presentations.
Execution milestones: Advancement of XTX501 into Phase 1/2 trials, updated Phase 2 data for Vilastobart, and leadership strengthening.
Key risks: Clinical trial outcomes, regulatory approvals, financial sustainability, and competitive oncology market pressures.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

80
LLM visibility overview
LLM Visibility known facts
  • Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies.
  • The company has advanced its pipeline with XTX501, for which the FDA cleared an IND for a Phase 1/2 trial as of August 2026.
  • Xilio reported a preliminary 26% objective response rate in a Phase 2 trial of Vilastobart combined with Atezolizumab for metastatic MSS colorectal cancer as of May 2025.
  • The company has presented updated Phase 2 data for Vilastobart at the 2025 ASCO Annual Meeting.
  • Xilio appointed Yariv Houvras as Chief Medical Officer in September 2026 and Akintunde Bello, Ph.D., to its Board of Directors in June 2025.
  • Financial figures from the latest SEC 10-Q filing as of September 30, 2026, include cash and equivalents of $122.2 million, current assets of $126.5 million, and current liabilities of $26.8 million, resulting in a current ratio of 4.72 and a cash ratio of 4.56, indicating strong liquidity.
  • The company reported a net loss of $5.95 million and basic and diluted EPS of -$0.30 for the quarter ending September 30, 2026.
  • Xilio has conducted public offerings raising capital, including a $50 million public offering announced in June 2025 with potential total gross proceeds of $150 million.
  • Recent quarterly reports show losses with some quarters missing revenue estimates, but Q1 2026 showed a loss with revenue exceeding expectations.
  • The company is advancing its tumor-activated immuno-oncology pipeline with ongoing clinical trials and data presentations.
  • Xilio's business model centers on clinical development of novel oncology therapies with a focus on immuno-oncology and tumor activation mechanisms.
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-23 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-05-12 | www.nasdaq.com | Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/xilio-therapeutics-inc-xlo-reports-q1-loss-beats-revenue-estimates
  • N2 | 2026-05-12 | www.nasdaq.com | Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/opus-genetics-inc-ird-reports-q1-loss-misses-revenue-estimates
  • N3 | 2026-05-11 | www.nasdaq.com | Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/oculis-holding-ag-ocs-reports-q1-loss-lags-revenue-estimates
  • N4 | 2025-11-13 | www.nasdaq.com | Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/xilio-therapeutics-inc-xlo-reports-q3-loss-misses-revenue-estimates
  • N5 | 2025-11-12 | www.nasdaq.com | BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/bioxcel-therapeutics-inc-btai-reports-q3-loss-misses-revenue-estimates
  • N6 | 2025-09-29 | www.nasdaq.com | Friday's Biotech Bounce: Clinical Momentum Fuels Late-Day Gains | https://www.nasdaq.com/articles/fridays-biotech-bounce-clinical-momentum-fuels-late-day-gains
  • N7 | 2025-08-14 | www.nasdaq.com | Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/xilio-therapeutics-inc-xlo-reports-q2-loss-misses-revenue-estimates
  • N8 | 2025-08-14 | www.nasdaq.com | Xilio Revenue Jumps 246 Percent in Q2 | https://www.nasdaq.com/articles/xilio-revenue-jumps-246-percent-q2
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine